Journal Article

Improving TRansitions ANd outcomeS for heart FailurE patients in home health CaRe (I-TRANSFER-HF): a type 1 hybrid effectiveness-implementation trial: study protocol

Shum, Michelle, Ryvicker, Miriam B., Barrón, Yolanda, Kern, Lisa M., Goyal, Parag, Tobin, Jonathan N., Dodson, John A., Bowles, Kathryn H., Sterling, Madeline R., Ringel, Joanna Bryan, Arbaje, Alicia I., Cené, Crystal, McDonald, Margaret V., Spertus, Daniel, Rajan, Mangala, Banerjee, Samprit, Espinosa, Cisco G., Jones, Christine D., Safford, Monika M.

2024

Overview

Background Some of the most promising strategies to reduce hospital readmissions in heart failure (HF) is through the timely receipt of home health care (HHC), delivered by Medicare-certified home health agencies (HHAs), and outpatient medical follow-up after hospital discharge. Yet national data show that only 12% of Medicare beneficiaries receive these evidence-based practices, representing an implementation gap. To advance the science and improve outcomes in HF, we will test the effectiveness and implementation of an intervention called Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF), comprised of early and intensive HHC nurse visits combined with an early outpatient medical visit post-discharge, among HF patients receiving HHC. Methods This study will use a Hybrid Type 1, stepped wedge randomized trial design, to test the effectiveness and implementation of I-TRANSFER-HF in partnership with four geographically diverse dyads of hospitals and HHAs (“hospital-HHA” dyads) across the US. Aim 1 will test the effectiveness of I-TRANSFER-HF to reduce 30-day readmissions (primary outcome) and ED visits (secondary outcome), and increase days at home (secondary outcome) among HF patients who receive timely follow-up compared to usual care. Hospital-HHA dyads will be randomized to cross over from a baseline period of no intervention to the intervention in a randomized sequential order. Medicare claims data from each dyad and from comparison dyads selected within the national dataset will be used to ascertain outcomes. Hypotheses will be tested with generalized mixed models. Aim 2 will assess the determinants of I-TRANSFER-HF’s implementation using a mixed-methods approach and is guided by the Consolidated Framework for Implementation Research 2.0 (CFIR 2.0). Qualitative interviews will be conducted with key stakeholders across the hospital-HHA dyads to assess acceptability, barriers, and facilitators of implementation; feasibility and process measures will be assessed with Medicare claims data. Discussion As the first pragmatic trial of promoting timely HHC and outpatient follow-up in HF, this study has the potential to dramatically improve care and outcomes for HF patients and produce novel insights for the implementation of HHC nationally. Trial registration This trial has been registered on ClinicalTrials.Gov (#NCT06118983). Registered on 10/31/2023, https://clinicaltrials.gov/study/NCT06118983?id=NCT06118983&rank=1 .

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Adaptation / Beneficiaries / Cardiology / Care and treatment / COVID-19 / Diseases / Effectiveness studies / Female / Health Administration / Health care policy / Health Informatics / Health services / Heart Failure / Heart Failure - therapy / Home care / Home Care Services / Home health care / Hospitalization / Hospitals / Humans / Implementation Science / Intervention / Medicare / Medicine / Medicine & Public Health / Methods / Multicenter Studies as Topic / Nursing care / Nursing Research / Patient Discharge / Patient outcomes / Patient Readmission - statistics & numerical data / Patient Transfer / Public Health / Quality Improvement / Quality management / Randomized Controlled Trials as Topic / Relapse / Sepsis / Study Protocol / Telemedicine / Transitional care / United States